Tumour tissue transport after intraperitoneal anticancer drug delivery

Abstract Intraperitoneal (IP) drug delivery, either as an intraoperative chemoperfusion or as an adjuvant, repeated instillation, is an established treatment modality in patients with peritoneal carcinomatosis. The efficacy of IP drugs depends on its ability to penetrate the tumour stroma in order to reach their (sub)cellular target. It is known, that drug penetration after IP delivery is limited to a few millimetres. Here, we review the basic tissue transport mechanisms after IP delivery and discuss the biophysical barriers and obstacles that limit penetration distance. In addition, we review the physical and pharmaceutical interventions that have been studied in order to improve delivery of small molecular and macromolecular drugs after IP instillation. These interventions could inform the design of future clinical trials aiming at an improved efficacy of IP-based drug delivery in carcinomatosis patients.

[1]  Patrick Segers,et al.  Modelling drug transport during intraperitoneal chemotherapy , 2017, Pleura and peritoneum.

[2]  S. Shany,et al.  Vitamin D and Myofibroblasts in Fibrosis and Cancer: At Cross-purposes with TGF-β/SMAD Signaling. , 2016, Anticancer research.

[3]  R. Fässler,et al.  Integrin-mediated mechanotransduction , 2016, The Journal of cell biology.

[4]  R. Jain,et al.  Noninvasive Assessment of Losartan-Induced Increase in Functional Microvasculature and Drug Delivery in Pancreatic Ductal Adenocarcinoma1 , 2016, Translational oncology.

[5]  E. Ruoslahti,et al.  iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes. , 2016, Biomaterials.

[6]  E. Förster,et al.  Irradiation Does Not Increase the Penetration Depth of Doxorubicin in Normal Tissue After Pressurized Intra-peritoneal Aerosol Chemotherapy (PIPAC) in an Ex Vivo Model. , 2016, In vivo.

[7]  A. Oldberg,et al.  The Tyrosine Kinase Inhibitor Imatinib Augments Extracellular Fluid Exchange and Reduces Average Collagen Fibril Diameter in Experimental Carcinoma , 2016, Molecular Cancer Therapeutics.

[8]  R. Giavazzi,et al.  Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics , 2016, Chinese journal of cancer.

[9]  A. Merlino,et al.  Cisplatin binding to proteins: A structural perspective , 2016 .

[10]  M. McAleer,et al.  Survival and toxicity following sequential multimodality treatment including whole abdominopelvic radiotherapy for patients with desmoplastic small round cell tumor. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  M. Vannier,et al.  A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma , 2016, Pancreas.

[12]  R. Holcombe,et al.  Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer , 2016, Clinical Cancer Research.

[13]  B. Hylander,et al.  Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[14]  I. Tannock,et al.  Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors , 2015, Cancer science.

[15]  F. Starr,et al.  Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer. , 2015, Cancer research.

[16]  Christian Vanhove,et al.  Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model , 2015, Oncotarget.

[17]  E. Ruoslahti,et al.  A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[18]  U. Nielsen,et al.  Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302) , 2015, Molecular Cancer Therapeutics.

[19]  Gary Box,et al.  Exploring the biomechanical properties of brain malignancies and their pathologic determinants in vivo with magnetic resonance elastography. , 2015, Cancer research.

[20]  P. Dankers,et al.  Targeting the peritoneum with novel drug delivery systems in peritoneal carcinomatosis: a review of the literature. , 2015, Anticancer research.

[21]  E. Sassaroli,et al.  Modulation of the interstitial fluid pressure by high intensity focused ultrasound as a way to alter local fluid and solute movement: insights from a mathematical model , 2014, Physics in medicine and biology.

[22]  Edward J. Kim,et al.  Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma , 2014, Clinical Cancer Research.

[23]  G. Wahl,et al.  Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy , 2014, Cell.

[24]  Urszula Zaleska-Dorobisz,et al.  Ultrasound elastography - review of techniques and its clinical applications. , 2014, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[25]  S. Peters,et al.  Low-Dose Vascular Photodynamic Therapy Decreases Tumor Interstitial Fluid Pressure, which Promotes Liposomal Doxorubicin Distribution in a Murine Sarcoma Metastasis Model1 , 2014, Translational oncology.

[26]  T. Oda,et al.  Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1 , 2014, British Journal of Cancer.

[27]  W. Solass,et al.  Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience. , 2014, Gynecologic oncology.

[28]  I. Tannock,et al.  Use of the Proton Pump Inhibitor Pantoprazole to Modify the Distribution and Activity of Doxorubicin: A Potential Strategy to Improve the Therapy of Solid Tumors , 2013, Clinical Cancer Research.

[29]  Rakesh K. Jain,et al.  Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels , 2013, Nature Communications.

[30]  Urs Giger-Pabst,et al.  Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy , 2013, Annals of Surgical Oncology.

[31]  E. Young.  Cells, tissues, and organs on chips: challenges and opportunities for the cancer tumor microenvironment. , 2013, Integrative biology : quantitative biosciences from nano to macro.

[32]  N. Forbes,et al.  Microfluidic technique to measure intratumoral transport and calculate drug efficacy shows that binding is essential for doxorubicin and release hampers Doxil. , 2013, Integrative biology : quantitative biosciences from nano to macro.

[33]  W. Solass,et al.  Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Occupational Health and Safety Aspects , 2013, Annals of Surgical Oncology.

[34]  J. Erler,et al.  Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK , 2013, Oncogene.

[35]  J. Remon,et al.  Optimization of Drug Delivery Systems for Intraperitoneal Therapy to Extend the Residence Time of the Chemotherapeutic Agent , 2013, TheScientificWorldJournal.

[36]  W. Solass,et al.  Renal and Hepatic Toxicities After Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) , 2013, Annals of Surgical Oncology.

[37]  B. Chauffert,et al.  High Pressure Enhances the Effect of Hyperthermia in Intraperitoneal Chemotherapy With Oxaliplatin: An Experimental Study , 2012, Annals of surgery.

[38]  I. Pastan,et al.  Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[39]  H. Kosmehl,et al.  Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. , 2012, Cancer research.

[40]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[41]  Y. Maitani,et al.  Collagenase-1 injection improved tumor distribution and gene expression of cationic lipoplex. , 2012, International journal of pharmaceutics.

[42]  S Pili-Floury,et al.  Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study , 2011, British Journal of Cancer.

[43]  R. Bleichrodt,et al.  Hyperthermia and Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis: An Experimental Study , 2011, Annals of surgery.

[44]  Rakesh K. Jain,et al.  Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.

[45]  Anurag K. Singh,et al.  Mild elevation of body temperature reduces tumor interstitial fluid pressure and hypoxia and enhances efficacy of radiotherapy in murine tumor models. , 2011, Cancer research.

[46]  R. Jain,et al.  Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors , 2011, Proceedings of the National Academy of Sciences.

[47]  B. Chauffert,et al.  Comparison of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a murin model of peritoneal carcinomatosis , 2011, Journal of experimental & clinical cancer research : CR.

[48]  Erkki Ruoslahti,et al.  Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs , 2010, Science.

[49]  B. Chauffert,et al.  Intraoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I study , 2010, Anti-cancer drugs.

[50]  G. Salvesen,et al.  Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma , 2009, BMC Cancer.

[51]  Erkki Ruoslahti,et al.  Tissue-penetrating delivery of compounds and nanoparticles into tumors. , 2009, Cancer cell.

[52]  Wilson Mok,et al.  Multiscale measurements distinguish cellular and interstitial hindrances to diffusion in vivo. , 2009, Biophysical journal.

[53]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[54]  Victor Frenkel,et al.  Pulsed high intensity focused ultrasound mediated nanoparticle delivery: mechanisms and efficacy in murine muscle. , 2009, Ultrasound in medicine & biology.

[55]  Valerie M. Weaver,et al.  A tense situation: forcing tumour progression , 2009, Nature Reviews Cancer.

[56]  Rakesh K Jain,et al.  In vivo imaging of extracellular matrix remodeling by tumor-associated fibroblasts , 2009, Nature Methods.

[57]  J. Au,et al.  Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer , 2008, Journal of Pharmacology and Experimental Therapeutics.

[58]  M. Markman.  Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. , 2008, Trends in pharmacological sciences.

[59]  Michael A Henson,et al.  Integrating cell-cycle progression, drug penetration and energy metabolism to identify improved cancer therapeutic strategies. , 2008, Journal of theoretical biology.

[60]  M. Flessner.  Endothelial Glycocalyx and the Peritoneal Barrier , 2008, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[61]  J. Houghton,et al.  Tumor microenvironment: The role of the tumor stroma in cancer , 2007, Journal of cellular biochemistry.

[62]  Alastair H Kyle,et al.  Limited Tissue Penetration of Taxanes: A Mechanism for Resistance in Solid Tumors , 2007, Clinical Cancer Research.

[63]  Michel Simonet,et al.  High Intra-abdominal Pressure Enhances the Penetration and Antitumor Effect of Intraperitoneal Cisplatin on Experimental Peritoneal Carcinomatosis , 2006, Annals of surgery.

[64]  Alex Vitkin,et al.  Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors. , 2006, Cancer research.

[65]  Cynthia A. Reinhart-King,et al.  Tensional homeostasis and the malignant phenotype. , 2005, Cancer cell.

[66]  B. Gustavsson,et al.  Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous Vasopressin in non-resectable pancreas cancer , 2005, Cancer Chemotherapy and Pharmacology.

[67]  Y. Boucher,et al.  Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  A. Sundin,et al.  5-FU uptake in peritoneal metastases after pretreatment with radioimmunotherapy or vasoconstriction: an autoradiographic study in the rat. , 2005, Anticancer research.

[69]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[70]  C. Davies,et al.  Collagenase Increases the Transcapillary Pressure Gradient and Improves the Uptake and Distribution of Monoclonal Antibodies in Human Osteosarcoma Xenografts , 2004, Cancer Research.

[71]  Timothy W Secomb,et al.  A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. , 2004, Neoplasia.

[72]  O. Kaalhus,et al.  Radiation Improves the Distribution and Uptake of Liposomal Doxorubicin (Caelyx) in Human Osteosarcoma Xenografts , 2004, Cancer Research.

[73]  Olivier De Wever,et al.  Role of tissue stroma in cancer cell invasion , 2003, The Journal of pathology.

[74]  Brian Seed,et al.  Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation , 2003, Nature Medicine.

[75]  F. Stewart,et al.  Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC). , 2003, Anticancer research.

[76]  D. Miklavčič,et al.  Effect of hydralazine on interstitial fluid pressure in experimental tumours and in normal tissue. , 2001, In vivo.

[77]  S N Gardner,et al.  A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. , 2000, Cancer research.

[78]  B. Chauffert,et al.  Epinephrine enhances penetration and anti‐cancer activity of local cisplatin on rat sub‐cutaneous and peritoneal tumors , 1999, International journal of cancer.

[79]  E. Sanidas,et al.  Peritoneal expansion by artificially produced ascites during perfusion chemotherapy. , 1999, Archives of surgery.

[80]  J Christodoulou,et al.  Cisplatin Binding Sites on Human Albumin* , 1998, The Journal of Biological Chemistry.

[81]  M. Flessner,et al.  Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. , 1997, Journal of the National Cancer Institute.

[82]  P. Sugarbaker,et al.  Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. , 1996, Anti-cancer drugs.

[83]  R. Jain,et al.  Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. , 1996, Cancer research.

[84]  S. Howell,et al.  Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[85]  R. Jain,et al.  Photodynamic therapy-induced alterations in interstitial fluid pressure, volume and water content of an amelanotic melanoma in the hamster. , 1994, British Journal of Cancer.

[86]  S. D. De Smedt,et al.  Nanomedicine‐based intraperitoneal therapy for the treatment of peritoneal carcinomatosis — Mission possible?☆ , 2017, Advanced drug delivery reviews.

[87]  M. Dewhirst,et al.  A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure. , 1997, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[88]  P. Sminia,et al.  Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. , 1991, European journal of cancer.

[89]  J G McVie,et al.  Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. , 1990, Cancer chemotherapy and pharmacology.

[90]  R K Jain,et al.  Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. , 1989, Microvascular research.